By Denise Baez
Treatment of symptomatic coronavirus disease 2019 (COVID-19) with nirmatrelvir plus ritonavir resulted in a risk of progression to severe COVID-19 that was 89% lower than the risk with placebo, without evident safety concerns, according to a study published in The New...